May 2025 FDA DRUG APPROVAL: Emrelis (telisotuzumab vedotin) 🫁 Mechanism of Action: Emrelis is a c-Met-directed antibody-drug conjugate (ADC) that targets cancer cells with high c-Met protein overexpression and delivers a cytotoxic payload to destroy them. 🫁 Indication: Approved for locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (≥50% tumor cells with strong staining). 🫁 Side Effects: Common adverse reactions include peripheral neuropathy, fatigue, decreased appetite, and peripheral edema. Become a part of our dynamic LinkedIn community to stay updated on the latest trends in publishing, research, and pharmaceutical webinars. Gain access to exclusive insights and opportunities that can enhance your career. Follow us today and embark on the SPSR journey with us! https://www.linkedin.com/company/spsr2010